After six straight months of gains, the index saw a sharp drop in October that even positive earnings news could not stave off.
The firm said genomic testing volume rose 23 percent year over year, and raised its revenue guidance for full-year 2018.
Analysts cited Guardant's strong liquid biopsy testing portfolio, specifically its Guardant360 assay, as reasons for their optimistic views.
The investment bank said that PacBio's SMRT sequencing technology has always been attractive compared to traditional NGS shotgun sequencing.
The analyst said Myraid's GeneSight and NIPT products present near-term opportunities that "should help power earnings upside in the years to come."
The investment bank said it is encouraged by the company's strong pipeline and position among its competitors but sees further upside for its stock.
Analyst Puneet Souda said HTG has a growing funnel of biopharma projects that have the potential to convert to companion diagnostics with regulatory approval.
The study solidified how doctors should interpret and act upon an intermediate result from the breast cancer risk test in how to treat early-stage patients.
The firm provided full-year 2018 revenue and adjusted earnings guidance that fell below Wall Street's expectations.
The investment bank gave the company's stock an Outperform rating with a target price of $90 per share.
A new study finds that a placental protein linked with preeclampsia can be targeted by RNA silencing, according to the New Scientist.
A settlement is expected in a Duke University lawsuit hinging on using falsified data to win grants, Retraction Watch and Science report.
In PNAS this week: approach for analyzing the expression of endogenous retroviruses, circular RNAs that influence host-virus interactions, and more.
A phylogenetic analysis finds that the rare hemimastigotes form their own supra-kingdom, CBC reports.